dc.contributor.author | Ertesvåg, Nina Urke | |
dc.contributor.author | Cox, Rebecca Jane | |
dc.contributor.author | Jalloh, Sarah Larteley Lartey | |
dc.contributor.author | Mohn, Kristin Greve-Isdahl | |
dc.contributor.author | Brokstad, Karl Albert | |
dc.contributor.author | Trieu, Mai Chi | |
dc.date.accessioned | 2023-01-02T10:14:33Z | |
dc.date.available | 2023-01-02T10:14:33Z | |
dc.date.created | 2022-09-26T09:06:06Z | |
dc.date.issued | 2022 | |
dc.identifier.issn | 2059-0105 | |
dc.identifier.uri | https://hdl.handle.net/11250/3040244 | |
dc.description.abstract | History of influenza A/H3N2 exposure, especially childhood infection, shape antibody responses after influenza vaccination and infection, but have not been extensively studied. We investigated the breadth and durability of influenza A/H3N2-specific hemagglutinin-inhibition antibodies after live-attenuated influenza vaccine in children (aged 3-17 years, n = 42), and after inactivated influenza vaccine or infection in adults (aged 22-61 years, n = 42) using 14 antigenically distinct A/H3N2 viruses circulating from 1968 to 2018. We found that vaccination and infection elicited cross-reactive antibody responses, predominantly directed against newer or future strains. Childhood H3-priming increased the breadth and magnitude of back-boosted A/H3N2-specific antibodies in adults. Broader and more durable A/H3N2-specific antibodies were observed in repeatedly vaccinated adults than in children and previously unvaccinated adults. Our findings suggest that early A/H3N2 exposure and frequent seasonal vaccination could increase the breadth and seropositivity of antibody responses, which may improve vaccine protection against future viruses. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Nature | en_US |
dc.rights | Navngivelse 4.0 Internasjonal | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/deed.no | * |
dc.title | Seasonal influenza vaccination expands hemagglutinin-specific antibody breadth to older and future A/H3N2 viruses | en_US |
dc.type | Journal article | en_US |
dc.type | Peer reviewed | en_US |
dc.description.version | publishedVersion | en_US |
dc.rights.holder | Copyright 2022 The Author(s) | en_US |
dc.source.articlenumber | 67 | en_US |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 1 | |
dc.identifier.doi | 10.1038/s41541-022-00490-0 | |
dc.identifier.cristin | 2055221 | |
dc.source.journal | npj Vaccines | en_US |
dc.relation.project | Norges forskningsråd: 284930 | en_US |
dc.identifier.citation | npj Vaccines. 2022, 7, 67. | en_US |
dc.source.volume | 7 | en_US |
dc.source.issue | 1 | en_US |